WO1997010832A1 - Treatment and prevention of hiv infection and aids with sarcoid-derived antigens - Google Patents
Treatment and prevention of hiv infection and aids with sarcoid-derived antigens Download PDFInfo
- Publication number
- WO1997010832A1 WO1997010832A1 PCT/US1996/014614 US9614614W WO9710832A1 WO 1997010832 A1 WO1997010832 A1 WO 1997010832A1 US 9614614 W US9614614 W US 9614614W WO 9710832 A1 WO9710832 A1 WO 9710832A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigen
- sarcoid
- kveim
- hiv
- amount
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 77
- 102000036639 antigens Human genes 0.000 title claims abstract description 77
- 108091007433 antigens Proteins 0.000 title claims abstract description 77
- 201000000306 sarcoidosis Diseases 0.000 title claims abstract description 56
- 208000031886 HIV Infections Diseases 0.000 title claims abstract description 23
- 238000011282 treatment Methods 0.000 title claims description 12
- 230000002265 prevention Effects 0.000 title claims description 8
- 208000037357 HIV infectious disease Diseases 0.000 title abstract description 13
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 title abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 25
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims abstract description 7
- 238000007918 intramuscular administration Methods 0.000 claims description 10
- 230000001965 increasing effect Effects 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000001990 intravenous administration Methods 0.000 claims description 7
- 238000001361 intraarterial administration Methods 0.000 claims description 6
- 238000007912 intraperitoneal administration Methods 0.000 claims description 6
- 238000007920 subcutaneous administration Methods 0.000 claims description 6
- 229960005486 vaccine Drugs 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 208000030507 AIDS Diseases 0.000 abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000001388 Opportunistic Infections Diseases 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract description 2
- 239000000725 suspension Substances 0.000 description 18
- 210000004027 cell Anatomy 0.000 description 10
- 241000725303 Human immunodeficiency virus Species 0.000 description 8
- 238000002347 injection Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 210000000952 spleen Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 206010018691 Granuloma Diseases 0.000 description 3
- 102000013462 Interleukin-12 Human genes 0.000 description 3
- 108010065805 Interleukin-12 Proteins 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940117681 interleukin-12 Drugs 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003028 elevating effect Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 201000003651 pulmonary sarcoidosis Diseases 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 108010041397 CD4 Antigens Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 101100289792 Squirrel monkey polyomavirus large T gene Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003237 epithelioid cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000019734 interleukin-12 production Effects 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000000207 lymphocyte subset Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002956 necrotizing effect Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
Abstract
A method for treating or preventing HIV infection and AIDS by administering antigens derived from sarcoidosis-infected tissue. The sarcoid antigens are administered by a route allowing for entry into the bloodstream and stimulate the production of CD4+ T helper cells, thus reducing the potential for HIV infection and AIDS and the susceptibility of HIV-1 infected individuals to opportunistic infections, or to AIDS-defining diseases.
Description
TREATMENT AND PREVENTION OF HIV INFECTION AND AIDS WITH SARCOI -DERIVED ANTIGENS
Field of the Invention The present invention relates to the treatment and prevention of HIV infection and AIDS by administration of antigens derived from sarcoidosis-infected tissue.
Background of the Invention Sarcoidosis, also called sarcoid of Boeck, is a chronic, progressive, systemic granulomatous reticulosis of unknown etiology which may involve almost any organ or tissue. The disorder is characterized by the presence in all affected organs or tissues by the accumulation of non-necrotizing epithelioid cell tubercles. The disease can be diagnosed by intracutaneous injection of a suspension of human sarcoidal spleen tissue known as the Kveim antigen (Siltzbach, J. Am. Med. ABSOC , 178:476-482, 1961) .
The Kveim antigen has been used as a diagnostic test to determine the presence of sarcoidosis in a patient. The traditional Kveim test for sarcoidosis is based on the skin's reactivity to injected sarcoid tissue. An intradermal injection of the test material is administered, and, if a noncaseating granuloma appears on the skin at the site in 4 to 8 weeks, the so-called Kveim reaction is positive and is evidence that the recipient has sarcoidosis. The amount of Kveim antigen injected in a diagnostic test is small; roughly two spleens supply between 2,000 and 3,000 Kveim test dosages (Siltzbach, J. Am. Med. Assoc , 178:476-482, 1961; de Bois et al., Lancet, 342:173, 1993).
Acquired immune deficiency syndrome (AIDS) is caused by a retrovirus, the human immunodeficiency virus (HIV) . HIV infection is characterized by a dramatic decrease in T lymphocytes (Th cells) carrying the CD4 antigen, although HIV- infected individuals can generate new T lymphocytes until late in the progress of the disease. The decline in the population of Th cells renders the HIV-infected individual susceptible to a large number of opportunistic infections, any of which may prove fatal. To date, there are no effective treatments for
AIDS or the HIV infection.
There are few reports of coexistence of sarcoidosis and HIV. As of May 1995, only nine cases had been reported (Granieri et al. , Southern Med. J. , 88:591-595, 1995; Newman et al., Chest, 102:1899-1901, 1992). The difference between the immune responses seen in HIV-infected patients and those with sarcoidosis is striking in that they are almost diametrically opposed. It is believed that sarcoid activates the immune system by markedly increasing the number of CD4* T helper cells.
This activation is often expressed as a comparison of the ratio of lymphocyte or T-cell subsets. Th cells have been defined above as expressing the CD4 surface antigen. Another large T cell subset are the killer lymphocytes, so called because they attack infected tissue. This cell subset carries a surface antigen called CD8. The CD4+/CD8+ ratio, or count, is the parameter characteristic of AIDS and sarcoidosis.
This distinction is most striking in pulmonary sarcoidosis cases, where researchers find a dramatic increase in this ratio in patients with sarcoidosis, and a profound decrease in the ratio in HIV positive patients. In the bronchoalveolar lavage (BAL) fluid of healthy, nonsmoking individuals, the CD4+/CD8+ ratio is approximately 1.6. In those with pulmonary sarcoidosis, there is a relative increase of CD4* over CD8+ cells and the CD4* to CD8+ ratio can rise to 10:1. In contrast, studies of BAL fluid in HIV-infected persons lacking clinical evidence of lung disease, show that 70% have a change in the amount of lymph cells due to a marked decrease in CD4+ cells and increase in CD8+ cells leading to a correspondingly lowered CD4+/CD8+ ratio (Chosia et al. , Pne mol . Alergol . Pol . , 59 (9-10) :23-27; Newman et al. , Chest, 102:1899-1901, 1992; Hunninghake, Ann. Intern. Med. , 94:73-94, 1981; Murray et al. , Am. Rev. Respir. Dis . , 141:1356-1372, 1990) . There is an urgent need for a safe, effective prevention and treatment of HIV infection and AIDS which is provided by the present invention.
Summary of the Invention One embodiment of the present invention is a method of treating HIV-1 infection and AIDS in a patient in need thereof, comprising the step of administering to the patient an effective CD4+-increasing amount of a sarcoid antigen in a pharmaceutically acceptable carrier. Preferably, the effective CD4+-increasing amount results in an absolute CD4+ count of greater than 500/mm3 and a CD4*/CD8+ ratio of about 1.5. Advantageously, the sarcoid antigen is Kveim antigen. In another aspect of this preferred embodiment, the Kveim antigen is administered in an amount ranging from about 0.10 ml to about 1.00 ml; more preferably, the amount is between about 0.20 and about 0.40 ml; most preferably, the amount is about 0.25 ml. Preferably, the administering step is intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous; most preferably, the administering step is intramuscular.
Another embodiment of the invention is a method for preventing HIV-1 infection and AIDS in an individual at risk therefor, comprising the step of administering to the individual an effective CD4+-increasing amount of a sarcoid antigen in a pharmaceutically acceptable carrier. Preferably, the sarcoid antigen is Kveim antigen. Advantageously, the Kveim antigen is administered in an amount ranging from about 0.10 ml to about 1.00 ml; more advantageously, the amount is between about 0.20 and about 0.40 ml; most advantageously, the amount is about 0.25 ml. According to another aspect of this embodiment, the administering step is intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous. Most preferably, the administering step is intramuscular.
The present invention also provides a vaccine composition for preventing HIV-1 infection and AIDS, comprising a sarcoid antigen in a pharmaceutically acceptable carrier. Preferably, the sarcoid antigen is Kveim antigen. Another embodiment of the invention is a method of increasing the CD4+ count in an individual in need thereof, comprising the step of administering to the individual an
effective CD4*-increasing amount of a sarcoid antigen in a pharmaceutically acceptable carrier. Preferably, the effective CD4+-increasing amount results in an absolute CD4* count of greater than 500/mm3 and an effective CD4+-increasing amount results in a CD4+/CD8+ ratio of about 1.5. Advantageously, the sarcoid antigen is Kveim antigen, preferably, the Kveim antigen is administered in an amount ranging from about 0.10 ml to about 1.00 ml; more preferably, the amount is between about 0.20 and about 0.40 ml; most preferably, the amount is about 0.25 ml. In another aspect of this embodiment, the administering step is intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous. Preferably, the administering step is intramuscular.
Detailed Description of the Preferred Embodiments The present invention relates to the immunotherapeutic treatment and prevention of HIV infection and AIDS in a human by administration of antigens derived from sarcoidosis- infected tissues. These sarcoid antigens will effectively stimulate the immune system, resulting in an elevation in the absolute CD4+ count or in the CD4+/CD8+ ratio and, consequently, exert both a protective effect in high risk individuals by acting as a therapeutic vaccine; and will promote improvement in the health of HIV-infected individuals and those with AIDS by preventing many opportunistic infections.
HIV-1 inhibits cytokine (i.e. interleukin) production; conversely, sarcoid antigen stimulates the production of cytokines, particularly interleukin-12 (IL-12) . Thus, sarcoid antigens will stimulate IL-12 production which will be measured and used to assess the status of HIV-1 infection. The HIV-1 viral load/burden will also be determined during the course of treatment with sarcoid antigen by measuring mRNA levels using, for example, an HIV mRNA assay kit available from Hoffmann-LaRoche. The total body viral load/burden will progressively decrease during sarcoid antigen treatment.
The introduction of immunogenic sarcoid antigen into a patient infected with HIV will "trick" the immune system into
responding to a perceived sarcoidosis disease process, thus stimulating the immune response by elevating the Th cell population to offset or block the progression of HIV infection and AIDS. The sarcoid antigen will also stimulate recruitment of CD4* cells from the circulating blood pool into the unhealthy organs affected by HIV.
The sarcoid antigen may be administered in a number of ways, as long as it can enter the bloodstream by the selected route. Preferred routes of administration include intramuscular, intravenous, intraarterial, intraperitoneal and subcutaneous. Intramuscular administration is particularly preferred. Although any sarcoid antigens capable of eliciting an increase in the absolute CD4+ count CD4+/CD8* ratio or IL-12 levels are contemplated for use in the present invention, the Kveim antigen is preferred.
It will be appreciated that the amount and frequency of administration of sarcoid antigens will vary depending on the particular antigen employed, the progression of the disease and the physical characteristics of the patient. In a preferred embodiment, up to five intramuscular injections of Kveim antigen, described below, are sequentially administered over a six month period in an amount ranging from about 0.10 ml to about 1.00 ml per injection. Booster administrations may be required at 6 month to one year intervals. In another preferred embodiment, up to four injections are administered during a 30 day period. For example, the Kveim antigen may be administered at day 0 followed by booster injections at days 4, 6 and 14. In a particularly preferred embodiment, the amount of Kveim antigen administered is between about 0.20 ml and 0.40 ml. In a most preferred embodiment, the amount of antigen administered is about 0.25 ml. The antigen is typically administered with a conventional amount of an adjuvant such as alum or Freund's complete adjuvant, although any conventional adjuvant known to one skilled in the art may be utilized. The Kveim antigen is used as a standardized suspension which is not usually quantitated. The antigen is used to test for sarcoidosis in a patient. If
a granuloma forms after injection into a patient having sarcoidosis, then the Kveim preparation is active.
The patient's blood is drawn weekly during the treatment and the absolute CD4* count and CD4+/CD8+ ratio are monitored by standard flow cytometry methods such as fluorescence- activated cell sorting (FACS) using monoclonal antibodies directed to the CD4 and CD8 cell surface proteins. The sarcoid antigen administration is continued until a CD4+/CD8+ ratio of approximately 1.5 is obtained and/or the absolute CD4+ count is greater than 500/mm3. Alternatively, the antigen may be administered even after this ratio has been reached in order to keep the Th cell count sufficiently high.
The particular sarcoid antigen administered can be any antigen capable of elevating the absolute CD4+ count and/or CD4+/CD8+ ratio when administered to an AIDS or HIV-infected individual. One particular sarcoid antigen, the Kveim antigen, is a suspension of extracts of sarcoid spleen or lymph node known to contain sarcoid granulomas. Once isolated, the suspension is sterilized by phenolization, heated by steam pressure and autoclaved as described in Example 1. The suspension may be stored at -20°C for one week, then irradiated and heat-sealed.
The antigen preparation for parenteral administration may be in the form of a sterile injectable preparation, such as a sterile aqueous or oleaginous suspension. The suspension may be formulated according to methods well known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally- acceptable diluent or solvent, such as a solution in 1,3- butanediol. Suitable diluents include, for example, water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile fixed oils may be employed conventionally as a solvent or suspending medium. For this purpose, any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid may likewise be used in the preparation of injectable
preparations.
Kveim antigen suspension is obtained from sarcoid- infected human spleens as described below.
Example 1 Preparation of Kveim antiσen suspension
Kveim antigen suspension is prepared according to the preferred method of Teirstein (in Sarcoidosis, Lieberman, J. , ed. , pp.104-105, Grune & Stratton, San Diego, 1985). Sarcoidosis-infected human spleen removed for clinical reasons is stored at -20°C or lower and thawed as required. All steps are performed using sterile buffers and instruments in an enclosed cabinet or hood to prevent contamination. All solutions are kept at 4°C, and the KS suspension is kept on ice unless otherwise noted. The spleen is thawed and the cortex removed and discarded. A 100 gram section of spleen is homogenized in 5 volumes of phosphate-buffered saline (PBS) . The homogenate is subjected to two cycles of freeze-thaw and homogenized a second time. The homogenate is then centrifuged at 10,000 rpm for 30 minutes and the supernatant discarded. The pellet is washed by resuspension in 2-3 volumes PBS and centrifugation as above. This washing/centrifugation is repeated 3-4 times until the sample is free of hemoglobin. The pellets are resuspended in 3 volumes PBS and again homogenized. The suspension is forced through a sterile 40 mesh filter using a 50 ml syringe without a needle. The mesh screen is rinsed with a small volume of PBS and any remaining large solids are discarded. The sample is centrifuged at 15,000 rpm for 45 minutes and the supernatant discarded. The pellet is resuspended in 2 volumes sterile water and heated to 65°C for two hours with intermittent agitation. The suspension is centrifuged at 15,000 rpm for 45 minutes to remove soluble lipids, resuspended in PBS to 5-6 ml/ml solids, incubated at 65°C for one hour and sonicated for 1-2 minutes. The suspension is passed through a 100 mesh filter and any large solids are discarded. The suspension is then subjected to phenolization (0.25%) and exposure to gamma irradiation (Munro et al. , Thorax, 42:321-331, 1987).
The Kveim antigen suspension is then used to treat HIV-i infected individuals and individuals with AIDS as described in the following examples.
Example 2 Immunotherapeutic Treatment of HIV infection and AIDS
Blood is drawn from HIV-infected individuals or individuals with AIDS and their pretreatment CD4+/CD8* ratio and absolute CD4+ count determined by FACS. On day zero, the individuals are intramuscularly administered 0.25 ml of the Kveim suspension in saline produced according to Example 1 in Freund's complete adjuvant. An equal number of HIV-infected individuals are administered only saline. Booster injections of Kveim antigen or saline are administered at days 4, 6 and 14. At day 21, blood is drawn from both experimental groups and the absolute CD4* count and CD4+/CD8+ ratio are determined. Individuals who receive the Kveim antigen exhibit significantly increased CD4+ counts and/or increased CD4*/CD8+ ratios in comparison to individuals who receive only saline.
Example 3 Prevention of HIV infection and AIDS by
Therapeutic Vaccination
HIV-1 negative individuals, including those at high risk for HIV-1 infection and HIV-1 negative individuals exhibiting illnesses characteristic of HIV infection or AIDS, are administered a vaccine comprising the Kveim antigen as described in Example 2. High-risk individuals include those practicing unprotected sex with individuals whose HIV status is unknown, intravenous drug users and those receiving blood transfusions prior to 1985. The individuals are monitored over time for appearance of the HIV-1 virus or AIDS by conventional blood detection methods by changes in CD4+/CD8+ ratios and in the absolute CD4+ count, or development of opportunistic infections and AIDS-defining diseases.
Claims
1. A method of treating or inhibiting HIV-1 infection in an individual in need thereof, comprising the step of administering to said patient an effective CD4+-increasing amount of a sarcoid antigen in a pharmaceutically acceptable carrier.
2. The method of Claim 1, wherein said effective CD4*- increasing amount results in an absolute CD4+ count of greater than 500/mm3.
3. The method of Claim 1, wherein said effective CD4+- increasing amount results in a CD4+/CD8+ ratio of about 1.5.
4. The method of Claim 1, wherein said sarcoid antigen is Kveim antigen.
5. The method of Claim 4, wherein said Kveim antigen is administered in an amount ranging from about 0.10 ml to about
1.00 ml.
6. The method of Claim 5, wherein said amount is between about 0.20 and about 0.40 ml.
7. The method of Claim 6, wherein said amount is about 0.25 ml.
8. The method of Claim 1, wherein said administering step is selected from the group consisting of intramuscular, intravenous, intraarterial, intraperitoneal and subcutaneous.
9. A vaccine composition for inhibiting HIV-1 infection, comprising a sarcoid antigen in a pharmaceutically acceptable carrier.
10. The vaccine composition of Claim 9, wherein said sarcoid antigen is Kveim antigen.
11. A method of increasing the CD4* count in an individual in need thereof, comprising the step of administering to said individual an effective CD4+-increasing amount of a sarcoid antigen in a pharmaceutically acceptable carrier.
12. The method of Claim 11, wherein said effective CD4+- increasing amount results in an absolute CD4+ count of greater than 500/mm3.
13. The method of Claim 11, wherein said effective CD4+-
increasing amount results in a CD4*/CD8+ ratio of about 1.5.
14. The method of Claim 11, wherein said sarcoid antigen is Kveim antigen.
15. The method of Claim 14, wherein said Kveim antigen is administered in an amount ranging from about 0.10 ml to about 1.00 ml.
16. The method of Claim 15, wherein said amount is between about 0.20 and about 0.40 ml.
17. The method of Claim 16, wherein said amount is about 0.25 ml.
18. The method of Claim 11, wherein said administering step is selected from the group consisting of intramuscular, intravenous, intraarterial, intraperitoneal and subcutaneous.
19. A method of treating or inhibiting HIV-1 infection in an individual in need thereof, comprising the step of administering to said patient an effective HIV-1 viral burden/load-decreasing amount of a sarcoid antigen in a pharmaceutically acceptable carrier.
20. Sarcoid antigen for use in treatment or prevention of HIV-1 infection.
21. The sarcoid antigen of Claim 20, wherein said antigen is Kveim antigen.
22. Use of sarcoid antigen in the preparation of a medicament for treatment or prevention of HIV-1 infection.
23. The use of Claim 22, wherein said sarcoid antigen is
Kveim antigen.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU69747/96A AU6974796A (en) | 1995-09-21 | 1996-09-13 | Treatment and prevention of hiv infection and aids with sarcoid-derived antigens |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US412195P | 1995-09-21 | 1995-09-21 | |
| US60/004,121 | 1995-09-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO1997010832A1 true WO1997010832A1 (en) | 1997-03-27 |
Family
ID=21709259
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1996/014614 WO1997010832A1 (en) | 1995-09-21 | 1996-09-13 | Treatment and prevention of hiv infection and aids with sarcoid-derived antigens |
Country Status (2)
| Country | Link |
|---|---|
| AU (1) | AU6974796A (en) |
| WO (1) | WO1997010832A1 (en) |
-
1996
- 1996-09-13 AU AU69747/96A patent/AU6974796A/en not_active Abandoned
- 1996-09-13 WO PCT/US1996/014614 patent/WO1997010832A1/en active Application Filing
Non-Patent Citations (8)
| Title |
|---|
| AM. REV. RESPIR. DIS. (USA), 1990, Vol. 142, No. 4, LOWERY et al., "Sarcoidosis Complicated by HIV Infection: Three Case Reports and a Review of the Literature", pages 887-889. * |
| CAN. MED. ASSOC. J., 1990, Vol. 142, No. 2, GOWDA et al., "Concomitant Sarcoidosis and HIV Infection", pages 136-137. * |
| CHEST, April 1994, Vol. 105, No. 4, WHITLOCK et al., "Sarcoidosis and HIV Infection", pages 1299-1300. * |
| CHEST, August 1994, Vol. 106, No. 2, GILMAN et al., "Decreased Prevalence of HIV Seropositivity in Sarcoidosis", page 157S. * |
| CHEST, December 1992, Vol. 102, No. 8, NEWMAN et al., "Coexistent Sarcoidosis and HIV Infection", pages 1899-1901. * |
| CHEST, May 1992, Vol. 101, No. 5, AMIN et al., "Positive Kveim Test in Patients with Coexisting Sarcoidosis and Human Immunodeficiency Virus Infection", pages 1454-1456. * |
| CHEST, September 1990, Vol. 98, No. 3, HUANG et al., "Effect of Bronchoalveolar Lavage Fluid from Patients with Sarcoidosis or AIDS on Interleukin 1beta Release from Alveolar Macrophages", pages 576-580. * |
| SOUTHERN MEDICAL JOURNAL, May 1995, Vol. 88, No. 5, GRANIERI et al., "Sarcoid Myopathy in a Patient with Human Immunodeficiency Virus Infection", pages 591-595. * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU6974796A (en) | 1997-04-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Smith | Immunologic types of blastomycosis: a report on 40 cases | |
| Hiruma et al. | Systemic phaeohyphomycosis caused by Exophiala dermatitidis: Systemische Phäohyphomykose verursacht durch Exophiala dermatitidis | |
| Fox et al. | Impaired delayed hypersensitivity in primary biliary cirrhosis | |
| Osserman et al. | RAPID DIAGNOSTIC TEST FOR MYASTHENIA GRAVIS: INCREASED MUSCLE STRENGTH, WITHOUT FASCICULATIONS, AFTER INTRAVENOUS ADMINISTRATION OF EDROPHONIUM (TENSILON®) CHLORIDE | |
| US5858378A (en) | Pharmaceutical composition comprising cryptosporidium parvum oocysts antigen and whole cell candida species antigen | |
| Gay et al. | The herpes encephalitis problem, II | |
| Cohen et al. | Pneumonic plague in an untreated plague-vaccinated individual | |
| JPH08511263A (en) | Release and mobilization of hematopoietic cells | |
| Sauer | Whooping cough: new phases of the work on immunization and prophylaxis | |
| Piccolo et al. | Myasthenia gravis in a patient with chronic active hepatitis C during interferon-alpha treatment. | |
| Mortada et al. | Virus aetiology of Behçet's syndrome | |
| Van den Broek et al. | Limited value of acyclovir in the treatment of uncomplicated herpes zoster: a placebo-controlled study | |
| WO1997010832A1 (en) | Treatment and prevention of hiv infection and aids with sarcoid-derived antigens | |
| Ahmed et al. | Familial occurrence of pemphigus vulgaris | |
| Miller et al. | The intradermal reaction in amebiasis | |
| EP0302862A1 (en) | Treatment of cancers with gamma interferon | |
| Mullan et al. | Toxoplasmosis and myocarditis. | |
| Gerner et al. | Endodontic treatment and immunopathology of periapical granuloma in an AIDS patient | |
| Genné et al. | Tuberculosis of the thumb following a needlestick injury | |
| JPS60155121A (en) | Therapy for acquired immunological dysfunction syndrome | |
| EP0335726A2 (en) | Use of thymopentin and derivatives in treatment of HIV viremic patients | |
| CA1322168C (en) | Process for the remission of the symptoms associated with aids | |
| Michelson et al. | Endophthalmitis of drug abuse | |
| FINE et al. | Hemagglutination test of Middlebrook and Dubos in ocular tuberculosis | |
| Mayo et al. | Acute eosinophilic pneumonia in a patient infected with the human immunodeficiency virus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |